Wockhardt Stock Soars 12% as US FDA Grants Fast Track to Breakthrough Antibiotic Zaynich NDA
Share market
C
CNBC Awaaz•01/12/2025
Wockhardt Stock Soars 12% as US FDA Grants Fast Track to Breakthrough Antibiotic Zaynich NDA
- •Stock rose 12% after US FDA accepted NDA for Zaynich.
- •Zaynich is a novel β-lactam enhancer antibiotic.
- •FDA granted Fast Track status for Zaynich.
- •First Indian NCE to reach NDA stage.
- •Wockhardt's major breakthrough in anti-infectives.
Why it matters: This breakthrough could lead to faster access to new antibiotics for resistant infections.
✦
Related Articles
Loading more articles...
